Biotechnology

DUALITYBIO-B

Enn Bio-B Plans $40M Share Buyback; Founder to Add $5M Stake

DYM Biologics Unveils Six Independent Research Achievements at AACR Annual Meeting

HTI Publishes Research Report on Dyn Biosciences

Dewpoint Biotech Announces 2025 Earnings: Revenue Growth Amid Widening Losses

CICC Maintains Overweight Rating for Dynbiosci-B

Yewei Biotech Announces 2025 Annual Report with Revenue Decline and Widening Loss

DUALITYBIO-B released FY2024 Q4 earnings on March 23 (BJT), actual revenue HKD 500.77M, actual EPS HKD -50.3332

DUALITYBIO-B released FY2024 9 Months Earnings on March 23 (BJT), actual revenue HKD 1.601 B, actual EPS HKD -92.0263

DUALITYBIO-B released FY2025 Q3 earnings on March 23 (BJT), actual revenue HKD 340.41 M, actual EPS HKD -3.2135

DUALITYBIO-B released FY2024 Q3 earnings on March 23 (BJT), actual revenue HKD 521.76 M, actual EPS HKD -52.4431

DUALITYBIO-B released FY2025 9 Months Earnings on March 23 (BJT), with actual revenue of HKD 1.671 B and EPS of HKD -57.0538

DUALITYBIO-B released FY2025 Q4 earnings on March 23, 2026 (BJT), actual revenue HKD 346.29 M, actual EPS HKD -3.269

DUALITYBIO-B released FY2025 annual earnings on March 23 (BJT), actual revenue HKD 2.024 B (forecast HKD 1.82 B), actual EPS HKD -43.5269 (forecast HKD -37.4184)

MindImmune Bio Publishes Latest Clinical Data for ADC Drug, Phil Securities Sees Bright Future

DUALITYBIO-B to Release FY2025 Annual Earnings on March 23, 2026 (BJT), Forecast Revenue HKD 1.855 B, EPS HKD -38.3859

DinuBio Advances ADC Development and Secures Multiple Collaborations

Guotai Junan Raises Denovo Biosciences' Target Price to HKD 455.56

XYZ International Upgrades Denovabiologics to Buy, Citing Progress in ADC Pipeline

Microsoft Partners with InBrainNeuroelectronics on Next-Generation Brain-Computer Interfaces

Debiopharm Conducts R&D Day and Plans for Sci-Tech Innovation Board Listing

FAMEGLOW

ZHONGSHENJIANYE

TJCD

ZXZN QI-HOUSE

CENTRAL DEV H

NEW GONOW RV

HINSANG GROUP

JOLIMARK

MEGAIN

HAICHANG HLDG

02442

06651

09606

02575

02225

02657

09995

00290

02509

01530

EASY SMART GP(02442) rose 21.49%, with a trading turnover 53.3 Million HKD, and a year-to-date rose 109.8%. 51WORLD(06651) rose 15.21%, with a trading turnover 1.8 Billion HKD, and a year-to-date rose 37.8%. DUALITYBIO-B(09606) rose 10.81%, with a trading turnover 488.5 Million HKD, and a year-to-date rose 6.6%.

Top Gainers&Losers

EASY SMART GP

51WORLD

XUANZHUBIO-B

JINHAI MED TECH

FOREST CABIN

REMEGEN

GOFINTECH QUANT

QYUNS-B

3SBIO

Top 10 HK Stock Gainers (4.15)

159615

520880

588130

516820

588860

159102

159992

DualityBio announced that its new drug DB-1303 has been accepted for listing by the National Medical Products Administration. This drug targets HER2-positive unresectable or metastatic breast cancer patients, showing significant efficacy and good safety based on the results of Phase III clinical trials. DualityBio is collaborating with 3SBIO to promote the commercialization of DB-1303 in mainland China, Hong Kong, and Macau, and will continue to deepen its global strategic cooperation with BioNTech

Tasty Money

China Southern Hang Seng Biotech ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

ChinaAMC CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Yinhua CSI Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

GF CSI HK Innovative Drugs Industry ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

DUALITYBIO's new drug application for adult breast cancer has been accepted by the National Medical Products Administration, promoting commercialization in mainland China, Hong Kong, and Macau

In a report released yesterday, from GF Securities maintained a Buy rating on Duality Biotherapeutics, Inc., with a price target of HK$520.49.Easter Sale - 70% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Duality Biotherapeutics, Inc. is a Strong Buy with an average price target of HK$423.73.

Tip Ranks

GF Securities Remains a Buy on Duality Biotherapeutics, Inc. (9606)

Haitong International released a research report on DUALITYBIO, adjusting the target price to RMB 457.74, with a rating of "Outperform the Market." The report pointed out that DUALITYBIO's revenue last year was RMB 1.85 billion, a year-on-year decrease of 5%, mainly affected by revenue from licensing and collaboration agreements. R&D expenses remained flat, with a net loss attributable to the parent company of RMB 2.6 billion for the year. It is expected that the loss will decrease to RMB 1.05 billion in 2024, and the revenue forecasts for this year and next year have been adjusted to RMB 1.8 billion and RMB 1.7 billion, respectively

AASTOCKS

Haitong International gives DUALITYBIO a target price of 457.74 yuan and a rating of "Outperform the Market"

DualityBio announced that its new drug application for the core product DB-1303/BNT323 has been accepted by the National Medical Products Administration. This application is based on positive results from a Phase III pivotal clinical study aimed at evaluating the efficacy and safety of DB-1303 in patients with HER2-positive unresectable or metastatic breast cancer

BioNTech SE

DUALITYBIO's core product DB-1303/BNT323 listing application has been accepted

Duality Biotherapeutics has scheduled an extraordinary general meeting for April 29, 2026, in Shanghai, with a book closure period from April 24 to April 29, 2026. Shareholders must lodge share transfers by 4:30 p.m. on April 23, 2026, to participate. This announcement highlights the company's commitment to corporate governance and regulatory compliance. The latest analyst rating for Duality Biotherapeutics (HK:9606) is a Buy, with a price target of HK$383.47, and the company has a market cap of HK$28.01B.

Duality Biotherapeutics Sets April 29, 2026 Extraordinary General Meeting and Book Closure Dates

03317

02632

02616

01458

03339

01093

03696

06127

09887

XUNCE(03317) rose 24.26%, with a trading turnover 2.2 Billion HKD, and a year-to-date rose 273.3%. NEW VISION CO(02632) rose 23.93%, with a trading turnover 36.2 Million HKD, and a year-to-date rose 31.2%. CSTONE PHARMA-B(02616) rose 20.72%, with a trading turnover 613.5 Million HKD, and a year-to-date rose 58.1%.

XUNCE

NEW VISION CO

CSTONE PHARMA-B

ZHOU HEI YA

LONKING

CSPC PHARMA

INSILICO

JOINN

LEADS BIOLABS-B

Top 10 HK Stock Gainers (3.27)

DUALITYBIO-B announced its annual results for 2025, with revenue of 1.852 billion yuan, a year-on-year decrease of 4.6%; gross profit of approximately 589 million yuan, down 33.2%. Losses widened to 2.595 billion yuan, with a loss per share of 39.8 yuan, and no final dividend was declared. The company has reached a cooperation agreement with 3SBio to advance the commercialization of HER2 ADC and has made positive progress in clinical trials

DUALITYBIO (9606) reported a loss of 2.6 billion last year, with gross profit declining by 34% year-on-year and no final dividend declared

STRO

DUALITYBIO-B announced the appointment of Zhang Shaoren as the company's Chief Financial Officer, effective from the day before (23rd)

DUALITYBIO-B(09606.HK)